Education
About Us
Working with TipRanks
Follow Us
Rebus Holdings Inc (RBSH)
:RBSH
RBSH Stock Chart & Stats
<$0.01
<$0.01(9900.00%)
At close: 4:00 PM EST
<$0.01
<$0.01(9900.00%)
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
Volume402.00
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$5.00K
Total Debt (Recent Filing)$310.00K
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.05
Price to Sales (P/S)0.00
P/FCF Ratio-0.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
RBSH FAQ
What was Rebus Holdings Inc’s price range in the past 12 months?
Currently, no data Available
What is Rebus Holdings Inc’s market cap?
Currently, no data Available
When is Rebus Holdings Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rebus Holdings Inc’s earnings last quarter?
Currently, no data Available
Is Rebus Holdings Inc overvalued?
According to Wall Street analysts Rebus Holdings Inc’s price is currently Overvalued.
Does Rebus Holdings Inc pay dividends?
Rebus Holdings Inc does not currently pay dividends.
What is Rebus Holdings Inc’s EPS estimate?
Rebus Holdings Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rebus Holdings Inc have?
Currently, no data Available
What happened to Rebus Holdings Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rebus Holdings Inc?
Currently, no hedge funds are holding shares in RBSH
Company Description
Rebus Holdings Inc
Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company was founded in 2003 and is based in Westlake Village, California.
Ownership Overview
―
Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---